Journal of Clinical Immunology

, Volume 11, Issue 2, pp 103–113 | Cite as

T-cell abnormality and defective interleukin-2 production in patients with carcinoma of the urinary bladder with schistosomiasis

  • Syed Raziuddin
  • Sugandh Shetty
  • Ahmed Ibrahim
Original Articles

Abstract

Patients with schistosomiasis of the urinary bladder (SB) and schistosomiasis with carcinoma of the urinary bladder (SCB) had significantly increased percentage of IL-2R-, HLA-DR-, and transferrin receptor (T9)-bearing T cells in circulation. The percentage of these activated T cells decreased byin vitro culture with PHA but increased bySchistosoma haematobium soluble egg antigen. These patients with SB and SCB had a PHA-specific defect in IL-2 production. A functional defect with induction of IL-2R-positive suppressor monocytes appears to correlate with the defective PHA-induced IL-2 production by CD4+ T cells and monocytes. Disordered regulation of PHA-induced IL-2 production by the CD4+ T cells and monocytes may be the key feature in the highly depressed cell-mediated immune response in schistosomiasis. However, immune activation and significantly elevated IL-2 production in response to disease-specificS. haematobium soluble egg antigen may be related with the pathogenesis of SB and SCB. Thus,S. haematobium-specific CD4+ T cells are present in schistosomiasis, and their function is determined by adequate release of IL-2-and/or IL-2R-bearing CD11+ suppressor monocytes.

Key words

Schistosomiasis carcinoma of bladder CD4+ T cells interleukin-2 phytohemagglutinin T-cell activation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Smithers SR, Doenhoff MI: Schistosomiasis.In Immunology of parasitic infections, S Cohen, KS Warren (eds). Blackwell Scientific, Oxford, 1982, p 527Google Scholar
  2. 2.
    Bloom BR: Games parasites play. How parasites evade immune surveillance. Nature 279:21–26, 1979Google Scholar
  3. 3.
    Sebai ZA: Schistosomiasis in Saudi Arabia. Ann Saudi Med 3:269–174, 1988Google Scholar
  4. 4.
    Ottesen EA: Modulation of the host response in human schistosomiasis. I. Adherent suppressor cells that inhibit lymphocyte proliferative response to parasite antigen. J Immunol 123:1639–1646, 1979Google Scholar
  5. 5.
    Capron A, Dessain JP: Effector and regulatory mechanism in immunity to schistosomiasis. A heuristic review. Annu Rev Immunol 3:455–476, 1985Google Scholar
  6. 6.
    Warren KS: Hepatosplenic schistosomiasis mansoni. An immunologic disease. Bull NY Acad Med 51:545–554, 1975Google Scholar
  7. 7.
    Warren KS: The secret of immunopathogenesis of schistosomiasis: In vivo models. Immunol Rev 61:189–213, 1982Google Scholar
  8. 8.
    Mahmoud AAF: Current concepts: Schistosomiasis. Med Intell 297:1329–1332, 1977Google Scholar
  9. 9.
    Ellner JJ, Olds GR, Kamel R, Osman GS, El-Kholy A: Mahmoud AAF: Suppressor splenic T lymphocytes in human hepatosplenic schistosomiasis mansoni. J Immunol 125:308–311, 1980Google Scholar
  10. 10.
    Abdel-Tawab GA, Kelada FS, Kelada NI: Studies on the etiology of bilharzial cancer of the urinary bladder. Int J Cancer 1:377–382, 1966Google Scholar
  11. 11.
    Ezzat E, Osman RA, Ahmed KY, Soothil JF: The association between schistosoma haematobium infection and heavy proteinurea. Trans Roy Soc Trop Med Hyg 68:315–318, 1974Google Scholar
  12. 12.
    Raziuddin S, Shetty S, Ibrahim A, Patil K: Activated CD4+ T lymphocytes and impaired cell mediated immunity in patients of carcinoma of the urinary bladder with schistosomiasis. Cancer 65:931–939, 1990Google Scholar
  13. 13.
    Boros DL, Warren KS: Delayed hypersensitivity type granuloma formation and dermal reaction induced and elicited by a soluble factor isolated from schistosoma mansoni eggs. J Exp Med 132:488–507, 1970Google Scholar
  14. 14.
    Carter CE, Colley DG: An electrophoretic analysis of schistosoma mansoni egg antigen preparation. J Parasitol 64:385–390, 1978Google Scholar
  15. 15.
    Raziuddin S, Hussain NK, Latif ABA: A monoclonal antibody and functional study of malignant T cells of a patient with suppressor T cell lymphoma. Clin Immunol Immunopathol 45:230–234, 1987Google Scholar
  16. 16.
    Wysocki L, Sato VL: Panning of lymphocytes. A method for cell selection. Proc Natl Acad Sci USA 75:2844–2847, 1978Google Scholar
  17. 17.
    Raziuddin S, Kibler RF, Morrison DC: Immunosuppression of experimental allergic encephalomyelitis. III.In vitro evidence for induction of suppressor T lymphocytes in lymph nodes of animals immunized with myelin basic protein complexed to lipopolysaccharides. J Immunol 128:2073–2080, 1982Google Scholar
  18. 18.
    Mittler R, Rao P, Olini G, Westberg E, Newman W, Goldstein G: Activated human B cells display a functional IL-2 receptor. J Immunol 134:2393–2397, 1985Google Scholar
  19. 19.
    Herrmann F, Cannistra SA, Levine H, Griffin JD: Expression of interleukin-2 receptors and binding of interleukin-2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med 162:1111–1116, 1985Google Scholar
  20. 20.
    Holter W, Grunow R, Stockinger H, Knapp W: Recombinant interferon-y induces interleukin 2 receptors on human peripheral blood lymphocytes. J Immunol 136:2171–2175, 1986Google Scholar
  21. 21.
    Smith KA: Interleukin 2. Annu Rev Immunol 2:319–333, 1984Google Scholar
  22. 22.
    Stobo JD: Immunosuppression in man: Suppression by macrophages can be mediated by interactions with regulatory T cells. J Immunol 119:918–923, 1977Google Scholar
  23. 23.
    Gazzinelli G, Lambertucci JR, Katz N, Rocha RS, Lima MS, Colley DG: Immune responses during human schistosomiasis mansoni. XI. Immunologic status of patients with acute infections and after treatment. J Immunol 135:2121–2127, 1985Google Scholar
  24. 24.
    Luft BJ, Pedrott PW, Remington JS: In vitro generation of adherent mononuclear cells to toxoplasma antigen. Immunology 63:643–648, 1988Google Scholar
  25. 25.
    Piessens WS, Rattiwanto S, Tuti S, Palmieri JK, Piessens PW, Koiman I, Dennis DT: Antigen specific suppressor cells and suppressor factors in human filariasis with brugia malayi. N Engl J Med 302:333–338, 1980Google Scholar
  26. 26.
    Peterson EA, Neva FA, Barral A, Lorrea-Cornas R, Bogaeart-Diaz H, Martinoz D, Ward EE: Monocyte suppression of antigen-specific response in diffuse cutaneous leishmaniasis patients from the Dominican Republic. J Immunol 132:2603–2611, 1984Google Scholar
  27. 27.
    Toosi Z, Kleinhenz ME, Ellner JJ: Defective interleukin 2 production and responsiveness in human pulmonary tuberculosis. J Exp Med 163:1162–1172, 1986Google Scholar
  28. 28.
    Mohageghpour N, Gilber RH, Larrick JL, Sasaki DT, Bernnan PJ, Engleman EC: Defective cell mediated immunity in leprosy. Failure of T cells from leprosy patients to respond to mycobacterium leprae is associated with defective expression of IL-2 receptors and is not reconstituted by interleukin 2. J Immunol 135:1443–1449, 1985Google Scholar
  29. 29.
    Arno JN, Toosi Z, Edmonds K, Ellner JJ, Schmidt D: Decreased IL-2 production during reactivation of recurrent oral herpes simplex infection. Clin Res 32:363A, 1984 (abstr)Google Scholar
  30. 30.
    Harel-Bellan A, Joskowicz M, Eisen H: Modification of T cell proliferation and interleukin 2 production in mice infected with trypanosoma cruzi. Proc Natl Acad Sci USA 80:3466–3469, 1983Google Scholar
  31. 31.
    Reiner NE, Finke JH: Interleukin 2 deficiency in murine leishmaniasis donovani and its relationship to depressed spleen cell response to phytohemagglutinin. J Immunol 131:1487–1491, 1983Google Scholar
  32. 32.
    Kierszenbaum F, Bettz LA: Decreased human IL-2 receptor expression due to a protozoan pathogen. Immunol Today 10:129–131, 1989Google Scholar
  33. 33.
    Maizel AL, Ford RJ, Lachman LB: Effect of IL-1 on human thymocytes and human purified T cells. J Exp Med 155:943–952, 1981Google Scholar
  34. 34.
    Mizel SB: Interleukin 1 and T cell activation. Immunol Rev 63:51–69, 1982Google Scholar
  35. 35.
    Rappaport RS, Dodge G: Prostaglandin E inhibits the production of human interleukin 2. J Exp Med 155:943–952, 1982Google Scholar
  36. 36.
    Walker C, Kristensen F, Bettens F, DeWeck AL: Lymphokine regulation of activated lymphocytes. I. Prostaglandin E2 induced inhibition of interleukin 2 production. J Immunol 130:1770–1776, 1983Google Scholar
  37. 37.
    Chouaib S, Welte K, Mertelsmann R, Dupont B: Prostaglandin E2 acts at two distinct pathway of T lymphocyte activation. Inhibition of IL-2 and down regulation of transferrin receptor expression. J Immunol 135:1172–1179, 1985Google Scholar
  38. 38.
    Waldmann TA: The structure, function and expression of interleukin 2 receptors on normal and malignant lymphocytes. Science 232:727–732, 1986Google Scholar
  39. 39.
    Rosenberg SA: The adoptive therapy of cancer using the transfer of activated lymphoid cells and IL-2. Semin Oncol 13:200–216, 1986Google Scholar

Copyright information

© Plenum Publishing Corporation 1991

Authors and Affiliations

  • Syed Raziuddin
    • 1
    • 2
  • Sugandh Shetty
    • 1
    • 2
  • Ahmed Ibrahim
    • 1
    • 2
  1. 1.Department of Clinical Immunology, and Department of UrologyKing Saud University, College of MedicineAbhaSaudi Arabia
  2. 2.Asir Central HospitalAbhaSaudi Arabia

Personalised recommendations